REFERENCES
- Lieberman H. A., Lachman L., Schwartz J. B. Pharmaceutical Dosage Forms. 2nd ed., Marcel Dekker, New York 1989; 195–246
- Bühler V. Kollidon—Polyvinylpyrrolidone for the Pharmaceutical Industry. 3rd ed., BASF AG. 1996; 191–272
- Wallace J. W., Capozzi J. T., Shangraw R. F. Pharm. Technol. 1983, September: 94–104
- Bolhius G. K. Manuf. Chem. 1988; 76(June)29–32
- Sheskey P. J., Dasbach T. P., Tina P. Pharm. Technol. 1995; 19(10)98, 100, 102, 104, 106, 108, 110, 112
- Franz H., Weckenmann H. R. 1994, DE 4303846 A 1
- Krycer I., Pope D. G., Hersey J. A. Powder Technol. 1983; 34(1)53–56
- Delattre L. Expo. Congr. Int. Technol. Pharm. 1977; 2: 136–150
- Asker A. F., Saied K. M., Abdel-Khalek M. M. Pharmazie 1975; 30(4)236–238
- Rees J. E., Hall S. D. J. Pharm. Pharmacol. 1978; 26, suppl., Br. Pharm. Conf.
- Mazur J., Nyström C., Sjogren J. Acta Pharm. Suec. 1981; 18(2)95–96
- Nyström C., Glazer M. Int. J. Pharm. 1985; 23(3)255–263
- Kasa P., Pintye-Hodi K., Szabo-Revesz P., Miseta M., Selmeczi B., Traue J., Wenzel V. Pharmazie 1988; 43(11)780–781